医药生物行业周报：业绩修复周期开启，双主线聚焦“创新药+AI医疗”

信达证券2025-05-06

（以下内容从信达证券《医药生物行业周报：业绩修复周期开启，双主线聚焦“创新药+AI医疗”》研报附件原文摘录）本期内容提要:市场表现：上周（20250428-20250430）医药生物板块收益率为0.49%，板块相对沪深300收益率为0.93%，在31个一级子行业指数中涨跌幅排名第9。6个子板块中，医药商业板块周涨幅最大，涨幅为3.12%（相对沪深300收益率为3.56%）；跌幅最大的为生物制品，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533463235?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-06 16:08","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2533463235","market":"hk","top_or_hot":-1,"title":"医药生物行业周报：业绩修复周期开启，双主线聚焦“创新药+AI医疗”","media":"信达证券","content":"<div>\n<p>（以下内容从信达证券《医药生物行业周报：业绩修复周期开启，双主线聚焦“创新药+AI医疗”》研报附件原文摘录）本期内容提要:市场表现：上周（20250428-20250430）医药生物板块收益率为0.49%，板块相对沪深300收益率为0.93%，在31个一级子行业指数中涨跌幅排名第9。6个子板块中，医药商业板块周涨幅最大，涨幅为3.12%（相对沪深300收益率为3.56%）；跌幅最大的为生物制品，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506161143975067aa&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医药生物行业周报：业绩修复周期开启，双主线聚焦“创新药+AI医疗”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医药生物行业周报：业绩修复周期开启，双主线聚焦“创新药+AI医疗”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-06 16:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506161143975067aa&s=b><strong>信达证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>（以下内容从信达证券《医药生物行业周报：业绩修复周期开启，双主线聚焦“创新药+AI医疗”》研报附件原文摘录）本期内容提要:市场表现：上周（20250428-20250430）医药生物板块收益率为0.49%，板块相对沪深300收益率为0.93%，在31个一级子行业指数中涨跌幅排名第9。6个子板块中，医药商业板块周涨幅最大，涨幅为3.12%（相对沪深300收益率为3.56%）；跌幅最大的为生物制品，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506161143975067aa&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320764599.SGD","symbol_name":"FTIF - Templeton China A Acc SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506161143975067aa&s=b","article_id":"2533463235","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506161143975067aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2533463235","pubTimestamp":1746518928,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"本期内容提要:市场表现：上周医药生物板块收益率为0.49%，板块相对沪深300收益率为0.93%，在31个一级子行业指数中涨跌幅排名第9。我们认为随着医疗整顿负面影响逐步消化，院内市场有望逐步恢复，叠加院外消费医疗需求复苏，25Q2医药板块有望整体迎来业绩修复，建议重点关注复苏逻辑及经营改善逻辑的板块和个股，此外，随着降息降准预期提升，创新药+AI医疗主题仍有望成为下一阶段的进攻方向。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","BK1574":"生物医药B类股","06978":"永泰生物-B","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","01801":"信达生物","BK1521":"挪威政府全球养老基金持仓","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0823426480.USD":"法巴中国股票经典Dis","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0823426308.USD":"法巴中国股票基金","BK1589":"北水核心资产","02269":"药明生物","LU0052750758.USD":"富兰克林中国基金A Acc","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0051755006.USD":"摩根大通中国A (dist)","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","SG9999002463.SGD":"LionGlobal China Growth SGD","LU1720050803.USD":"安联全方位中国股票基金","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0181495838.USD":"施罗德新兴亚洲A Acc","BK1161":"生物科技","BK1610":"ETF&股票定投概念","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","09926":"康方生物"},"translate_title":"Pharmaceutical and Biological Industry Weekly Report: The performance recovery cycle has begun, and the dual main lines focus on \"innovative drugs + AI medical care\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":0.9,"06978":1,"09926":0.9,"01801":0.9},"content_text":"（以下内容从信达证券《医药生物行业周报：业绩修复周期开启，双主线聚焦“创新药+AI医疗”》研报附件原文摘录）本期内容提要:市场表现：上周（20250428-20250430）医药生物板块收益率为0.49%，板块相对沪深300收益率为0.93%，在31个一级子行业指数中涨跌幅排名第9。6个子板块中，医药商业板块周涨幅最大，涨幅为3.12%（相对沪深300收益率为3.56%）；跌幅最大的为生物制品，跌幅0.87%（相对沪深300：-0.43%）。25Q1业绩简要总结：截至25/4/30，医药个股25Q1业绩已披露99%（467家公司已披露业绩），其中收入和扣非归母净利润双增长的标的有155家（占已披露公司的33%）。若从收入增速上看，在已披露业绩的医药上市公司中，50%的公司在25Q1（共250家）收入下滑，将近23%的公司（共103家）收入增速在0-10%，13%的公司（共55家）收入增速在10%-20%，7%的公司（共29家）收入增速在20%-30%，7%的公司（共29家）收入增速在30%以上。其中，25Q1收入增速在30%以上的公司分别为迪哲医药、北陆药业、翰宇药业、亚虹医药、兴齐眼药、圣诺生物、康鹏科技、泽璟制药、海辰药业、艾力斯、康泰生物、金凯生科、诺泰生物、天智航、怡和嘉业、佰仁医疗、三友医疗、济南高新、康为世纪、易瑞生物、智翔金泰、艾迪药业、君实生物、荣昌生物、昊帆生物、甘李药业、长药控股、ST目药、特一药业。周观点：随着25Q1业绩逐步披露，医药板块出现结构性行情，一季度业绩较好的股价走势相对较强。我们认为随着医疗整顿负面影响逐步消化，院内市场有望逐步恢复，叠加院外消费医疗需求复苏，25Q2医药板块有望整体迎来业绩修复，建议重点关注复苏逻辑及经营改善逻辑的板块和个股，此外，随着降息降准预期提升，创新药+AI医疗主题仍有望成为下一阶段的进攻方向。创新药：我们认为25Q2创新药或有医保谈判、医保丙类目录落地预期、多个重要肿瘤药临床会议等事件催化。①商业化快速放量的创新药标的，建议关注信达生物、百济神州、云顶新耀、再鼎医药、康方生物、科伦博泰、再鼎医药、荣昌生物等；②具备较高研发亮点的创新药标的，建议关注泽璟制药、诺诚健华、亚盛医药、复宏汉霖、亿帆医药、众生药业等；③核药创新药高壁垒，关注中国同辐、东诚药业、远大医药。AI医疗：4月24日七部门联合印发《医药工业数智化转型实施方案（2025—2030年）》，提出到2030年规上医药工业企业基本实现数智化转型全覆盖的目标。我们认为2025年或是AI医疗快速发展的元年，①AI制药标的，AI模型可模拟药物分子与靶点相互作用，预测疗效和安全性，加速新药上市，建议关注晶泰控股、维亚生物、鸿博医药、成都先导。②AI诊断标的，诸如金域医学、迪安诊断、兰卫医学。③AI医疗服务，诸如美年健康、爱尔眼科、固生堂、海吉亚医疗、锦欣生殖；CRO研发服务，如药明康德、康龙化成、凯莱英、药明生物、泰格医药、普蕊斯、诺思格。④AI赋能医疗影像，如联影医疗、迈瑞医疗、万东医疗、开立医疗、澳华内镜等。⑤AI基因测序等，AI可以对基因组学、转录组学、蛋白质组学和代谢组学等数据，进行多维度的分析和挖掘，揭示生物系统的复杂调控网络，或将带动精准诊断发展，提升医疗行业对多组学数据的需求，建议关注华大智造、华大基因、达安基因、诺禾致源、贝瑞基因等。⑥AI医生，建议关注平安好医生、阿里健康、京东健康等平台。消费复苏条线：近期关于消费刺激的政策预期较强，消费医疗方向有望受益。①眼科口腔产业链，建议关注爱尔眼科、普瑞眼科、华厦眼科、爱博医疗、欧普康视、通策医疗、时代天使等；②医疗美容产业链，建议关注爱美客、华熙生物、华东医药、锦波生物、江苏吴中等；③中药补益类产品，建议重点关注东阿阿胶、同仁堂、片仔癀；④医药零售龙头，建议关注益丰药房、大参林、国药一致、老百姓、一心堂、健之佳等；⑤消费医疗器械企业，建议关注可孚医疗、三诺生物、怡和嘉业、美好医疗、鱼跃医疗。经营改善条线：①骨科耗材集采续标且手术量恢复增长，建议关注爱康医疗、春立医疗、康拓医疗；②新签订单增长有望带动业绩显著改善的CXO龙头公司，建议关注药明康德、凯莱英、康龙化成等；③经营改善带来业绩反转，建议关注广誉远、哈药股份、健民集团、立方制药等。④低估值稳健企业，建议关注振德医疗、维力医疗。风险因素：消费刺激政策变动风险；产品销售不及预期；临床数据不及预期；集采降价幅度高于预期；市场竞争加剧风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533463235","isCrawlerRequest":true}